CLAIMS

1. Use of a composition in the manufacture of a contraceptive medicament for a non-hormonal contraception method for a male subject, wherein said composition is an extended release formulation comprising:

    - an alpha-1-adrenoreceptor antagonist; and
    - at least one pharmaceutically acceptable carrier,

    wherein ~~the contraception method includes a once daily administration of~~ said composition is to be administered once daily at about the same time each day, triggering a continuous reversible aspermia, azoospermia, or severe oligozoospermia in the male subject,

    wherein after an initial period of at least two consecutive days, the contraception is not impaired by a delay of the subsequent once daily intake, and

    wherein the alpha-1-adrenoreceptor antagonist is *(R)*-silodosin.

2. The use according to claim 1, wherein the composition is adapted for oral administration.

3. The use according to claim 1 or claim 2, wherein the composition is adapted such that, after the initial period of consecutive days, the intake of a next dose can be delayed from 6 to 18 hours after the last regular daily dose time, and the condition of aspermia, azoospermia or severe oligozoospermia is maintained in the male subject.

4. The use according to any one of claims 1 to 3, wherein the composition is adapted such that after the initial period of consecutive days, failure to intake one daily dose does not affect the continuous state of aspermia, azoospermia or severe oligozoospermia supporting the contraception method for 36 to 48 hours as of the last intake time.

5. The use according to any one of claims 1 to 4, wherein the composition is adapted such that the contraception method is carried on for at least eight days.

6. The use according to any one of claims 1 to 5, wherein the alpha-1-adrenoreceptor antagonist is in an amount ranging from ~~about~~ 0.1 to ~~about~~ 30 mg.

7. The use according to claim 6, wherein the alpha-1-adrenoreceptor antagonist is in an amount ranging from 0.2 to 20 mg.

8. The use according to any one of claims 1 to 7, wherein *(R)*-silodosin is in a polymorphic or amorphous form.

9. The use according to any one of claims 1 to 8, wherein the composition includes or consists of at least one particle and the average particle diameter is in the range of 0.01 to 5 mm.

10. The use according to claim 9, wherein the composition includes or consists of at least one coated particle.

11. The use according to claim 9, wherein the average particle diameter is in the range of 0.1 to 2 mm.

12. The use according to any one of claims ~~1~~9 to 11, wherein the particles are encompassed into a capsule, each capsule being filled by particles in a number sufficient to reach the daily dose.

13. The use according to any one of claims 1 to 12, wherein the contraception is achieved independently from the food consumption by the male subject.

14. The use according to any one of claims 1 to 13, wherein the composition is adapted for simultaneous or sequential administration of an additional composition suitable for treating erectile dysfunction.

15. The use according to claim 14, wherein the additional composition comprises a phosphodiesterase-5 inhibitor.

~~16. Packaging comprising at least 7, 14, 28, 56, 84, or 168 to 365 unitary doses; or 10, 20, 30, 60, 90, or 180 to 360 unitary doses of the composition as described in any one of claims 1 to 15, each unitary dose being a daily dose.~~

~~17. Packaging according claim 16, wherein the composition includes *(R)* silodosin in an amount ranging from 0.1 to 30 mg.~~

~~18. The packaging according to claim 17, wherein the composition includes *(R)* silodosin in an amount ranging from 0.2 to 20 mg.~~

~~19. The packaging according to claim 18, wherein the composition includes *(R)* silodosin in an amount of 8 to 12 mg.~~